CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Mayo Clinic
Incyte Corporation
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Amgen
University of Rochester
M.D. Anderson Cancer Center
Dren Bio
West Virginia University
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Miltenyi Biomedicine GmbH
The University of Queensland
University of Miami
M.D. Anderson Cancer Center
BeOne Medicines
National Institutes of Health Clinical Center (CC)
University of Washington
Masonic Cancer Center, University of Minnesota
Quetzal Therapeutics
Technical University of Munich
Institute of Hematology and Blood Transfusion, Czech Republic
City of Hope Medical Center
Universität Duisburg-Essen
National Cancer Institute (NCI)
AVM Biotechnology Inc
New York Medical College
BeOne Medicines
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Therapeutic Advances in Childhood Leukemia Consortium
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
Immunome, Inc.
Children's Hospital of Philadelphia
Children's Hospital of Philadelphia
BeOne Medicines
BeOne Medicines
City of Hope Medical Center
Nantes University Hospital
Ohio State University Comprehensive Cancer Center
Orca Biosystems, Inc.
BeOne Medicines
Ohio State University Comprehensive Cancer Center
The First Affiliated Hospital of Soochow University